CORT:NSC-Corcept Therapeutics Incorporated (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 68.62

Change

0.00 (0.00)%

Market Cap

USD 1.00B

Volume

1.11M

Analyst Target

USD 15.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+11.61 (+2.40%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

+16.88 (+3.05%)

USD 69.68B
ARGX argenx NV ADR

+25.45 (+4.38%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+2.24 (+0.94%)

USD 30.51B
ONC BeiGene, Ltd.

+12.39 (+5.38%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.34 (+1.06%)

USD 19.31B
SMMT Summit Therapeutics PLC

+2.89 (+12.44%)

USD 14.57B
INSM Insmed Inc

+2.46 (+3.59%)

USD 12.52B
INCY Incyte Corporation

+2.35 (+4.13%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

+2.85 (+5.02%)

USD 11.50B

ETFs Containing CORT

ABLS Abacus FCF Small Cap Lead.. 11.53 % 0.00 %

+0.09 (+0.41%)

N/A
FORH Formidable ETF 3.05 % 0.00 %

+0.21 (+0.41%)

USD 0.02B
AFSM First Trust Active Factor.. 1.76 % 0.00 %

+0.32 (+0.41%)

USD 0.03B
IJT iShares S&P Small-Cap 600.. 1.08 % 0.25 %

+1.31 (+0.41%)

USD 5.40B
RTWO:LSE L&G Russell 2000 US Small.. 1.02 % 0.00 %

+2.97 (+0.41%)

USD 0.19B
RTWP:LSE Legal & General UCITS ETF.. 1.02 % 0.00 %

+150.50 (+0.41%)

USD 0.19B
QVMS Invesco Exchange-Traded F.. 0.66 % 0.00 %

+0.27 (+0.41%)

USD 0.16B
GSSC Goldman Sachs ActiveBeta.. 0.63 % 0.20 %

+0.60 (+0.41%)

USD 0.48B
BBSC JPMorgan BetaBuilders U.S.. 0.59 % 0.00 %

+0.66 (+0.41%)

USD 0.45B
SPSM SPDR® Portfolio S&P 600 .. 0.57 % 0.06 %

+0.45 (+0.41%)

USD 9.96B
IJR iShares Core S&P Small-Ca.. 0.55 % 0.07 %

+1.05 (+0.41%)

USD 70.99B
FLDZ Listed Funds Trust 0.50 % 0.00 %

+0.33 (+0.41%)

USD 3.65M
BKSE BNY Mellon ETF Trust - BN.. 0.41 % 0.00 %

+1.16 (+0.41%)

USD 0.10B
XRS2:SW Xtrackers Russell 2000 UC.. 0.38 % 0.00 %

+9.35 (+0.41%)

USD 1.82B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+3.82 (+0.41%)

N/A
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

+1.35 (+0.41%)

USD 1.11B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+0.92 (+0.41%)

USD 0.43B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.75 (+0.41%)

USD 0.16B
JSML Janus Henderson Small Cap.. 0.00 % 0.50 %

+0.75 (+0.41%)

USD 0.17B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

+2.57 (+0.41%)

USD 0.09B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

+51.90 (+0.41%)

USD 8.62M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.86 (+0.41%)

USD 8.52M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.18% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.18% 95% A 95% A
Trailing 12 Months  
Capital Gain 191.88% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 191.88% 98% N/A 98% N/A
Trailing 5 Years  
Capital Gain 473.75% 98% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 473.75% 98% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 29.08% 73% C 82% B
Dividend Return 29.08% 73% C 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.19% 65% D 39% F
Risk Adjusted Return 60.36% 97% N/A 84% B
Market Capitalization 1.00B 96% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 234.80 19% 21%
Price/Book Ratio 8.94 16% 13%
Price / Cash Flow Ratio 31.25 2% 9%
Price/Free Cash Flow Ratio 41.22 3% 8%
Management Effectiveness  
Return on Equity 23.81% 98% 92%
Return on Invested Capital 19.67% 89% 84%
Return on Assets 11.71% 98% 96%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.